Comparative Study of rhPDGF-BB Plus Equine-Derived Bone Matrix Versus rhPDGF-BB Plus β-TCP in the Treatment of Periodontal Defects.
Abstract: The purpose of this study was to evaluate the efficacy and safety of equine-derived bone matrix as a carrier for recombinant human platelet-derived growth factor BB (rhPDGF-BB) versus beta-tricalcium phosphate (β-TCP) for the treatment of intraosseous periodontal defects in adult patients. This study was performed on 32 adults with advanced periodontal disease. Eligible subjects were randomized in 1:1 ratio into a test (rhPDGF-BB-coated equine-derived bone matrix) or control group (rhPDGF-BB-coated β-TCP). Probing pocket depth (PD), clinical attachment level (CAL), gingival recession (GR), and defect depth on radiographs were measured at 2 weeks before surgery, on the day of surgery (DOS), and 6 months postsurgery (6MPS). The clinical and radiographic data were analyzed over the test period. Statistically significant PD reductions and CAL gain between baseline and 6MPS and between ODS and 6MPS were seen in both groups (P < .01). No statistically significant differences in PD reduction were found between groups. However, the test group showed significant CAL gain between DOS and 6MPS. The radiographic bone level change was statistically significant compared to baseline (P < .01) in both groups. The results suggested that equine-derived bone matrix is a viable, effective, and safe carrier scaffold for rhPDGF in periodontal defects.
Publication Date: 2017-10-13 PubMed ID: 29023613DOI: 10.11607/prd.3401Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Comparative Study
- Journal Article
- Randomized Controlled Trial
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research was conducted to determine the effectiveness and safety of equine-derived bone matrix and β-TCP, when used with recombinant human platelet-derived growth factor BB (rhPDGF-BB), in the treatment of periodontal defects. The study found both methods to be safe and effective, although the equine-derived bone matrix showed a notable improvement in clinical attachment level after surgery.
Objective of the Study
- The study aims to assess the safety and efficacy of equine-derived bone matrix and β-TCP (beta-tricalcium phosphate), when used as carriers for rhPDGF-BB, in treating intraosseous periodontal defects in adult patients. The goal is to identify the best approach to deal with periodontal disease.
Methodology
- Researchers randomly divided 32 adults affected by advanced periodontal disease into two groups. One had rhPDGF-BB combined with equine-derived bone matrix, while the control group had rhPDGF-BB combined with β-TCP.
- The measurement parameters included probing pocket depth (PD), clinical attachment level (CAL), gingival recession (GR), and defect depth on radiographs, calculated at 2 weeks before surgery, on the day of surgery (DOS), and 6 months postsurgery (6MPS).
Results
- Both test and control groups revealed significant reductions in the probing pocket depth (PD) and increase in the clinical attachment level (CAL) between the baseline and 6 months after surgery. This indicates that both methods are effective for treating periodontal defects.
- However, the test group (those administered the equine-derived bone matrix) showed a significant improvement in clinical attachment level from the day of surgery to 6 months after surgery. Therefore, the equine-derived bone matrix appears to offer more significant benefits in terms of clinical attachment level improvements.
- Both groups demonstrated a significant change in the radiographic bone level when compared to the baseline, suggesting that both methods have a strong impact on bone level changes and periodontal healing.
Conclusion
- The study concludes that using equine-derived bone matrix as a carrier for rhPDGF is a safe and effective treatment of periodontal defects.
- This research provides substantial insights for dental professionals when considering treatment options for periodontal disease.
Cite This Article
APA
Lee JY, Na HJ, Kim HM, Lee SC, Lee JY, Chung CP, Seol YJ, Park YJ.
(2017).
Comparative Study of rhPDGF-BB Plus Equine-Derived Bone Matrix Versus rhPDGF-BB Plus β-TCP in the Treatment of Periodontal Defects.
Int J Periodontics Restorative Dent, 37(6), 825-832.
https://doi.org/10.11607/prd.3401 Publication
Researcher Affiliations
MeSH Terms
- Adult
- Alveolar Bone Loss / therapy
- Animals
- Becaplermin
- Biocompatible Materials / administration & dosage
- Bone Matrix / transplantation
- Calcium Phosphates / administration & dosage
- Combined Modality Therapy
- Female
- Guided Tissue Regeneration, Periodontal
- Humans
- Male
- Middle Aged
- Periodontal Attachment Loss / therapy
- Proto-Oncogene Proteins c-sis / administration & dosage
- Recombinant Proteins / administration & dosage
- Treatment Outcome
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
